NR4A1 and breast carcinoma: Adjuvant endocrine therapy (AET) has substantial clinical benefits, including a reduction in breast cancer recurrence by 20% to 30% among women with hormone receptor–positive breast cancer.1,2 However, AET adherence remains a concern in the US,3,4 and Black women are more likely to have lower adherence compared with White women.5,6 Both physical and psychological symptoms are key barriers to AET adherence.7,8,9,10